SpringWorks Therapeutics [SWTX] - Last Close: $38.00
An upbeat clinical report is lifting shares of SpringWorks in the premarket.
The biotech firm reported its nirogacestat drug candidate achieved its primary and all key secondary endpoints in Phase 3 DeFi trials in adult patients with progressing desmoid tumors.
Clinical data shows the drug produced statistically significant improvements in progression-free survival compared to placebo, and statistically significant improvements were also achieved on all key secondary endpoints.
Additional data is expected to be presented at an upcoming medical conference set for the second half of 2022, and the company plans to submit a New Drug Application to the US Food & Drug Administration in the second half as well.
SWTX is one of this morning's top performers with a 19.6% premarket gain.